Arrowhead Pharmaceuticals (ARWR) Research & Development (2010 - 2026)

Arrowhead Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $173.3 million for Q1 2026.

• Quarterly Research & Development rose 30.17% year-over-year to $173.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $687.5 million (up 23.13% YoY) and the FY2025 annual result came in at $607.2 million, up 20.02% from the prior year.
• Research & Development was $173.3 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $177.2 million in the prior quarter.
• Across five years, Research & Development topped out at $177.2 million in Q4 2025 and bottomed at $72.2 million in Q2 2022.
• A 5-year average of $120.5 million and a median of $116.5 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development soared 70.0% — and 2023, when it dropped 1.45%.
• Arrowhead Pharmaceuticals' Research & Development stood at $83.7 million in 2022, then soared by 39.19% to $116.5 million in 2023, then gained by 17.61% to $137.0 million in 2024, then rose by 29.34% to $177.2 million in 2025, then decreased by 2.23% to $173.3 million in 2026.
• Business Quant data shows ARWR's Research & Development at $173.3 million in Q1 2026, $177.2 million in Q4 2025, and $174.7 million in Q3 2025.